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Abstract 
Cancer stem cells or cancer initiating cells are believed to contribute to cancer recurrence 
after therapy. MicroRNAs (miRNAs) are short RNA molecules with fundamental roles in 
gene regulation. The role of miRNAs in cancer stem cells is only poorly understood. Here we 
report miRNA expression profiles of glioblastoma stem cell-containing CD133+ cell 
populations. We find that miR-9, miR-9* (referred to as miR-9/9*), miR-17 and miR-106b 
are highly abundant in CD133+ cells. Furthermore, inhibition of miR-9/9* or miR-17 leads to 
reduced neurosphere formation and stimulates cell differentiation. Calmodulin-binding 
transcription activator 1 (CAMTA1) is a putative transcription factor, which induces the 
expression of the anti-proliferative cardiac hormone natriuretic peptide A (NPPA). We 
identify CAMTA1 as a miR-9/9* and miR-17 target. CAMTA1 expression leads to reduced 
neurosphere formation and tumor growth in nude mice suggesting that CAMTA1 can function 
as tumor suppressor. Consistently, CAMTA1 and NPPA expression correlate with patient 
survival. Our findings could provide a basis for novel strategies of glioblastoma therapy. 
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 Introduction 
MiRNAs are fundamental regulators of gene expression that direct processes as diverse as cell 
metabolism, lineage specification or cell differentiation (Bartel, 2009; Bushati & Cohen, 
2007). MiRNAs are small RNA molecules with a size of about 18-25 nucleotides (nt). 
MiRNA genes are transcribed to primary miRNA transcripts, which are processed to miRNA 
precursors (pre-miRNAs) by the microprocessor complex in the nucleus. Pre-miRNAs fold 
into characteristic hairpin structures and are transported into the cytoplasm, where Dicer 
processes pre-miRNAs and generates a short double stranded RNA. In further steps, one 
strand directly interacts with a member of the Argonaute (Ago) protein family (Hutvagner & 
Simard, 2008; Peters & Meister, 2007) and is incorporated into a miRNA-protein complex 
referred to as miRNP (Carthew & Sontheimer, 2009; Kim et al, 2009; Krol et al, 2010). The 
other strand, referred to as miRNA* (miRNA star), is degraded. In rare cases, however, both 
strands can give rise to functional miRNAs. One example for such a bifunctional miRNA is 
the miR-9/9* pair (Packer et al, 2008). MiRNAs guide miRNPs to partially complementary 
target sites on mRNAs and the miRNP-mRNA interaction leads to inhibition of translation or 
mRNA degradation (Huntzinger & Izaurralde, 2011). 
MiRNAs are fundamental regulators of basic cellular processes such as cell cycle control, cell 
differentiation and proliferation (Bartel, 2009; Bushati & Cohen, 2007) and are frequently de-
regulated in tumors (Calin & Croce, 2006; Croce, 2009; Esquela-Kerscher & Slack, 2006; 
Garzon et al, 2009). Numerous miRNA-profiling studies revealed that miRNA expression is 
altered in almost all types of cancer. Depending on the target mRNAs they regulate, miRNAs 
can be classified as tumor suppressors or oncogenes. The miRNAs miR-15 and miR-16 
(chronic lymphocytic leukemia, CLL), the let-7 family (lung and breast cancer) as well as 
miR-34 (pancreatic, colon and breast cancer) are well-characterized tumor suppressors (Calin 
et al, 2002; He et al, 2007; Johnson et al, 2005; Tarasov et al, 2007). On the other hand, 
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miRNAs such as miR-155 (lymphomas), the miR-17-92 (lymphomas) cluster or miR-21 
(variety of different cancers including glioblastomas) have been characterized as oncogenes 
(Chan et al, 2005; Costinean et al, 2006; He et al, 2005). 
Cell populations with stem cell-like properties including self-renewal and differentiation have 
been identified in a variety of tumors (Lobo et al, 2007). These cancer stem cells (also 
referred to as tumor initiating cells) can initiate tumor growth, whereas other tumor cells fail 
to form new tumors when injected into nude mice. Cancer stem cells can be enriched in cell 
fractions that express specific surface proteins, such as CD44 in breast cancer or CD133 in 
colorectal cancer and a subgroup of primary astrocytic glioblastoma (Gilbertson & Rich, 
2007; Lobo et al, 2007; Visvader & Lindeman, 2008; Tabatabai & Weller, 2011). According 
to the cancer stem cell hypothesis, cancer stem cells are believed to be the cause of relapse 
after therapy and contribute to teatment resistance (Reya et al, 2001). MiRNA expression 
profiling has been performed in several different tumor stem cell populations. In breast cancer 
cells, for example, it has been shown that let-7 regulates self-renewal and tumorigenicity of 
cancer initiating cells (Yu et al, 2007). Moreover, miR-34a is required for prostate cancer 
stem cell function and inhibition of miR-34a leads to reduced tumor growth (Liu et al, 2011). 
A detailed characterization of miRNA expression in glioblastoma stem cells has not yet been 
performed. 
Here we report the miRNA expression profile of CD133+ glioblastoma cell populations. We 
find that miR-9, miR-9*, miR-106b and miR-17 are highly abundant in glioblastoma stem 
cells. We further find that inhibition of miR-9/9* promotes neuronal differentiation 
suggesting that miR-9/9* inhibit differentiation of glioblastoma stem cells and maintain their 
stemness. We identify the calmodulin-binding transcription activator 1 (CAMTA1) as miR-
9/9* target. CAMTA1 over-expression substantially reduces colony formation, demonstrating 
that CAMTA1 is a novel tumor suppressor in glioblastoma. Consistently, we find that 
CAMTA1 expression correlates with glioblastoma patient survival. CAMTA1 is a putative 
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transcription factor and we show that CAMTA1 regulates the expression of the natriuretic 
peptide A (NPPA, also referred to as atrial natriuretic factor (ANF)), which gives rise to 
peptide hormones with anti-proliferative effects. 
 
Results 
miRNA expression profiling of CD133+ glioblastoma stem cells 
In order to analyze the contribution of miRNAs to the biology of glioblastoma stem cells, we 
isolated stem cell-containing CD133+ cells from the primary glioblastoma cell line R11 (Beier 
et al, 2007; Beier et al, 2008) by fluorescence-activated cell sorting (FACS, Figure 1A and 
1B). Total RNA was extracted from CD133+ and CD133- cells and small RNA libraries were 
generated and sequenced (Figure 1C and suppl. Table 1 and 2). A detailed analysis of the 
individual miRNAs revealed that miR-9*, miR-17-5p, miR-106b and miR-15b were highly 
abundant in CD133+ cells, whereas miR-221, miR-222, miR-27a and miR-21 were more 
specific to CD133- cells (Figure 1D). The sequencing data were further validated by Northern 
blotting. Signals for miR-17-5p, miR-9*, miR-106b and also miR-9 were much stronger in 
CD133+ cells (Figure 1E) demonstrating that these miRNAs are indeed differentially 
expressed between CD133+ and CD133- cells. Since the miR-9/9* pair was highly abundant 
in CD133+ R11 cells, we next confirmed the differential miR-9/9* expression in CD133+ cells 
in additional primary glioblastoma cell lines by qPCR (Beier et al, 2007) (Figure 1F). 
Consistent with the data obtained from R11 cells, miR-9/9* expression is increased in 
CD133+ cell populations of many glioblastoma cell lines, whereas miR-34a was either not 
changed or less abundant in CD133+ cells. Although miR-9/9* expression is always stronger 
in CD133+ cells (with the exception of miR-9* in R54 cells, middle panel), some cell lines 
show only mild differences in miR-9/9* expression in CD133+ cells compared CD133- cells. 
This might be due to the different tumor origin of the cell lines. 
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miR-9/9* are required for neurosphere formation and glioblastoma stem cell 
maintenance 
CD133+ glioblastoma cell populations show a neurosphere-like growth in tissue culture based 
colony formation assays. Therefore, we analyzed the impact of CD133+-specific miRNAs on 
neurosphere formation. Primary glioblastoma cells were transfected with 2’-O-methylated 
antisense inhibitors against miR-9, miR-9*, miR-17-5p or miR-106b and neurosphere growth 
was analyzed (Figure 2A and suppl. Figure 1 for validation of miRNA inhibition). Inhibition 
of miR-9 as well as miR-9* led to strongly reduced neurosphere formation. Inhibition of miR-
17-5p reduced colony formation significantly whereas miR-106b inhibition had no effect 
(Figure 2A). Conversely, transfection of a miR-9/9* mimic increased neurosphere formation 
of primary glioblastoma cells (Figure 2B). 
Since both inhibition of miR-9/9* and miR-17-5p affected neurosphere formation, we 
analyzed whether the simultaneous inhibition of two miRNAs caused additive effects (Figure 
2C). Indeed, the effects of miR-9 or miR-9* inhibition were significantly stronger, when miR-
17-5p was co-inhibited, suggesting that both miRNAs function independently of each other 
and contribute to neurosphere formation. Of note, much lower inhibitor concentrations were 
used for the double-inhibition experiments and therefore the overall numbers differ from the 
experiments shown in Figure 1A. 
Because miR-9/9* are highly abundant in CD133+ cells we asked if inhibition of these 
miRNAs may influence the CD133+ cell population. Primary glioblastoma cells were 
transfected with inhibitors against miR-9 or miR-9* and CD133+ cells were sorted (Figure 
2D). Indeed, inhibition of miR-9 or miR-9* led to a reduction of the CD133+ cell population, 
suggesting that both miRNAs are required for CD133+ glioblastoma stem cell maintenance. 
Reduced stem cell maintenance might lead to increased cell differentiation of primary 
glioblastoma cells. Thus, miR-9 or miR-9* was blocked and the neuronal differentiation 
marker Tuj1 or the glial marker GFAP were analyzed by Western blotting. Strikingly, 
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CD133+ cell-depleted populations exhibited induced neuronal differentiation as evident from 
increased Tuj1 expression, whereas glial differentiation appeared not to be affected by miR-
9/9* inhibition (Figure 2E). In summary, our data suggest that miR-9/9* help maintaining 
CD133+ cells probably by preventing differentiation. 
 
CD133+ cancer stem cell miRNAs regulate the putative transcription factor CAMTA1 
In order to understand the role of miR-9/9* in glioblastoma stem cells, it is important to know 
the identity of their individual target mRNAs. To find miR-9* targets in primary glioblastoma 
cells, we transfected inhibitors against miR-9* or control inhibitors and immunoprecipitated 
Ago2-bound mRNAs (Figure 3A) (Beitzinger et al, 2007; Easow et al, 2007; Karginov et al, 
2007). The miRNA inhibitor prevents mRNA binding and therefore miR-9* targets are 
selectively lost in the immunoprecipitates compared to control transfections. Using this 
approach, we identified a number of mRNAs that are strongly reduced in anti-Ago2 
immunoprecipitates when miR-9* was inhibited (Figure 3B). We focused on CAMTA1, 
because it is expressed from the 1p36 locus that is frequently deleted in a subset of gliomas 
(Finkler et al, 2007). Strikingly, a minimal deletion comprising only the CAMTA1 gene has 
been identified, suggesting that CAMTA1 is indeed important for glioma formation 
(Barbashina et al, 2005). 
We found that the CAMTA1 3’ untranslated region (UTR) not only contains binding sites for 
miR-9* but also for miR-9, miR-106b and miR-17-5p, which are also highly abundant in 
CD133+ cell populations (Figure 4A). The CAMTA1 3’ UTR was fused to firefly luciferase 
and co-transfected together with inhibitors against miR-9/9* (Figure 4B, panels 1 and 2), 
miR-106b (panel 3) or miR-17-5p (panel 3) into primary glioblastoma cells. In all cases, 
firefly expression was elevated upon miRNA inhibition. Increased firefly activity was not 
observed, when reporters with mutated miR-9 or miR-9* binding sites were transfected. 
Furthermore, endogenous CAMTA1 mRNA as well as protein levels were elevated, when 
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miR-9 or miR-9* was inhibited (Figure 4C and D). Of note, protein levels were much 
stronger increased than mRNA levels suggesting that miR-9/9* may preferentially inhibit 
CAMTA1 translation. Since miR-9 and miR-9* inhibition blocked neurosphere formation, we 
hypothesized that this effect could be mediated through the induction of CAMTA1. 
Therefore, CAMTA1 was depleted by RNAi in primary glioblastoma cells (suppl. Figure 2) 
and after 2 days, miR-9 or miR-9* was inactivated with antisense oligonucleotides (Figure 
4E). Indeed, miR-9 inhibition effects on colony formation were rescued by CAMTA1 
depletion. We also observed a significant rescue of miR-9* inhibition, although not as strong 
as observed for miR-9. 
 
CAMTA1 functions as tumor suppressor in glioblastoma cells 
It has been suggested that CAMTA1 functions as tumor suppressor in neuroblastoma (Finkler 
et al, 2007; Henrich et al, 2011). However, a link between CAMTA1 function and 
glioblastoma has not been reported so far. To address this question, we cloned the CAMTA1 
cDNA and transfected it into primary glioblastoma cells (Figure 5A, B and C). Strikingly, 
over-expression of CAMTA1 let to strongly reduced neurosphere formation both in R11 and 
R28 cells. CAMTA1 is a putative transcription factor that contains a N-terminal DNA binding 
domain (Figure 5A). We deleted the DNA binding domain (Figure 5D), transfected the 
mutated CAMTA1 into primary glioblastoma cells and again analyzed neurosphere 
formation. Interestingly, the ∆N mutant that cannot bind DNA has no inhibitory effect on 
colony formation, indicating that over-expression of functional CAMTA1 inhibits 
neurosphere formation. Since miR-9/9* negatively regulate CAMTA expression, we 
hypothesized that CAMTA1 over-expression should have a similar effect on the CD133+ cell 
compartment as miR-9/9* inhibition (see Figure 2B). Indeed, over-expression of CAMTA1 
reduced the number of CD133+ cells suggesting that the miR-9/9* effect is at least in part due 
to CAMTA1 inhibition (Figure 5E). 
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To further analyze the observed tumor suppressor activity of CAMTA1 in vivo, a R28 cell 
line stably expressing luciferase was transfected either with an empty plasmid or with a 
plasmid containing wild type (wt) CAMTA1 (Figure 6). After transfection, cells were injected 
into nude mice and tumor growth was analyzed 15 days after transfection by measuring 
luciferase activity. In agreement with the in vitro data, cells transfected with wt CAMTA1 
showed strongly decreased tumor growth, whereas control cells formed tumors rapidly 
(Figure 6A and 6B). In summary, we have shown that CAMTA1 functions as tumor 
suppressor both in vitro and in vivo. 
The striking effect of CAMTA1 over-expression on colony formation and tumor growth 
prompted us to ask whether CAMTA1 expression also correlates with survival of patients 
suffering from astrocytoma or glioblastoma. We analyzed mRNA expression data sets from 
large patient cohorts using the Repository of Molecular Brain Neoplasia Data 
(REMBRANDT) and The Cancer Genome Atlas (TCGA) (Figure 7A and B). CAMTA1 
mRNA expression was strongly decreased in astrocytoma as well as glioblastoma patients 
compared to healthy individuals. Notably, grade IV glioblastomas show lower CAMTA1 
expression than the less malignant astrocytomas. These results are in line with our previous 
results indicating a significant down-regulation of CAMTA1 mRNA in cancer stem cells 
compared to neural stem cells (Lottaz et al, 2010). Finally, we correlated glioblastoma patient 
survival with low or intermediate (blue) and high (red) CAMTA1 expression (Figure 7C). 
Strikingly, glioblastoma patients with high CAMTA1 levels survived much longer than 
patients with lower or intermediate CAMTA1 expression indicating that CAMTA1 is a tumor 
suppressor with a high prognostic value. 
 
CAMTA1 stimulates the expression of the anti-proliferative peptide NPPA 
It has been shown that CAMTA2, which is highly homologous to CAMTA1, activates 
transcription of the natriuretic peptide A (NPPA) in the heart (Song et al, 2006). Interestingly, 
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it has been demonstrated that NPPA has an anti-proliferative effect on glioblastoma cells in 
vitro (Vesely et al, 2007). We analyzed whether CAMTA1 also activates the expression of 
NPPA in glioblastoma cells. A plasmid expressing wt CAMTA1 or a mutant lacking the 
DNA-binding domain was transfected into LNT-229 cells and NPPA expression was 
analyzed by qPCR (Figure 8A). Wild-type CAMTA1 expression led to an increase of NPPA 
expression, while transfection of the mutated CAMTA1 had a much weaker effect. NPPA is a 
short secreted peptide, which is taken up by the natriuretic peptide receptor A (NPR-A). 
Therefore, we tested NPR-A expression and found that the receptor for NPPA is upregulated 
by CAMTA1 expression as well (Figure 8B). Finally, since miR-9, miR-9* and miR-17 
regulate CAMTA1 expression in CD133+ cells, we tested whether inhibition of these 
miRNAs induces NPPA or NPR-A expression. MiRNAs were inhibited using 2’-O-
methylated inhibitors and NPPA or NPR-A expression was subsequently analyzed by qPCR 
(Figure 8C). Strikingly, inhibition of miR-9/9* or miR-17 increased NPPA and NPR-A 
expression presumably by inducing CAMTA1 expression. 
NPPA has a strong anti-proliferative effect on glioblastoma cells in vitro and therefore we 
analyzed whether NPPA expression correlates with patient survival (Figure 7D). We used the 
REMBRANDT database for our investigations. Consistent with our experimental data, we 
found that expression of NPPA correlates with patient survival. Patients with high NPPA 
levels (red) survived much longer than patients with intermediate (blue) and low (green) 
NPPA levels. 
Taken together, we have found that miR-9/9* and miR-17 regulate the expression of the novel 
tumor suppressor CAMTA1 in CD133+ glioblastoma cells and CAMTA1 itself stimulates the 
expression of the anti-proliferative peptide NPPA. 
 
Discussion 
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MiRNAs have been implicated in almost all types of cancer (Calin & Croce, 2006; Esquela-
Kerscher & Slack, 2006; Garzon et al, 2009). However, only a few studies have analyzed the 
function of miRNAs in cancer stem cells (Ji et al, 2009; Shimono et al, 2009; Wong et al; Yu 
et al, 2007). We found that miR-9 and its corresponding miR-9* are highly expressed in 
cancer stem cell populations obtained from a subgroup of primary astrocytic glioblastomas. 
Both miRNAs function as oncogenes by repressing the novel tumor suppressor CAMTA1. 
Consistently, it has been shown that miR-9/9* are highly expressed in primary brain tumors 
(Huse et al, 2009; Nass et al, 2009). A recent study has analyzed miRNA expression in 261 
glioblastoma samples (Kim et al, 2011). According to their miRNA and mRNA expression 
profiles, glioblastomas were separated into five classes: glioblastomas with neural precursors, 
with oligoneural precursors, with multipotent precursors, with astrocytic precursors and with 
neuromesenchymal precursors. Interestingly, miR-9/9*, miR-17 or miR-106 were only found 
in glioblastomas with oligoneural precursors (Kim et al, 2011). It is thus unlikely that miR-
9/9* or miR-17 inhibition would affect all glioblastomas. It is more likely that only those 
tumors with oligoneural precursors are affected. These findings have also impact on possible 
therapeutic approaches. Glioblastomas need to be classified by miRNA expression profiling 
first before miRNA inhibition could be used as potential treatment. However, it is important 
to note that glioblastomas have been classified using various approaches and the obtained 
classes very often differ significantly (Huse et al, 2011; Lottaz et al, 2010; Phillips et al, 2006; 
Verhaak et al, 2010). 
MiR-9 has been implicated in cancer before. It is involved in cancer metastasis in breast 
cancer cells (Ma et al, 2010) or in colorectal cancer (Zhu et al, 2011). Interestingly, miR-9 
expression is stimulated by MYCN in breast cancer and MYCN is closely related to the 
frequent 1p36 deletion (Ma et al, 2010; Mestdagh et al, 2010). It is tempting to speculate that 
MYCN might contribute to miR-9/9* expression in glioblastoma as well. Very recently, it has 
been demonstrated that among others, expression levels of miR-9 and miR-17 are correlated 
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with malignant progression of gliomas (Malzkorn et al, 2010). In addition, miR-9 has been 
implicated in oligodendroglioma (Nelson et al, 2006). This supports our finding that these 
miRNAs are important for glioma pathogenesis. Furthermore, miR-9 is also important for 
neural development, neuronal stem cell fate determination and for proliferation and migration 
of neural progenitors (Delaloy et al, 2010; Yoo et al, 2009; Zhao et al, 2009) supporting our 
model that miR-9 is important for glioblastoma stem cell function. Our data provide evidence 
that the bi-functional miR-9/9* inhibits CAMTA1 expression in glioblastoma stem cells and 
thereby contributes to robust cancer stem cell survival. We have demonstrated that expression 
of CAMTA1 in glioblastoma cells causes a strong reduction of colony formation both in vitro 
and in a xenograft model system. Therefore, we suggest that CAMTA1 is a novel tumor 
suppressor gene functioning in glioblastoma. Strikingly, it has been shown very recently that 
CAMTA1 has tumor suppressor activity in neuroblastoma cells supporting the idea that 
CAMTA1 is a tumor suppressor in a larger variety of neural tumors (Henrich et al, 2011). 
The molecular functions of CAMTA1 have not been studied in detail yet. It has been shown 
in flies that CAMTA functions as transcription activator and is involved in the function of 
Rhodopsin, a G protein coupled light receptor (Han et al, 2006). In mammals, at least two 
CAMTA genes exist. The loss of CAMTA2 promotes cardiomyocyte hypertrophy (Song et al, 
2006). Since CAMTA proteins can activate the expression of NPPA in the heart, we asked 
whether NPPA might also play a role in glioblastoma. Indeed, it has been demonstrated that 
NPPA, when incubated with glioblastoma and also other cancer cells, has a strong anti-
proliferative effect in vitro (Vesely et al, 2007; Vesely et al, 2005). Strikingly, CAMTA1 
activates NPPA expression in glioblastoma cells as well. Moreover, CAMTA1 also stimulates 
the expression of the NPPA receptor, which might explain the tumor suppressor function of 
CAMTA1. Additionally, the NPPA gene is located in the 1p36 locus, and it is indeed deleted 
in a number of glioma (Ichimura et al, 2008). 
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Based on our data, we propose the following model. In CD133+ cells miR-9/9* and miR-17 
expression is high compared to CD133- cells, which results in low CAMTA1 expression. Of 
note, it is likely these miRNAs regulate several other target mRNAs, which might contribute 
to the observed phenotype as well. CAMTA1 inhibition also represses the expression of the 
secreted peptide NPPA. Upon CAMTA1 activation, NPPA expression is induced and the 
peptide is secreted. In parallel, CAMTA1 also stimulates the expression of the NPPA receptor 
NPR-A in order to allow cells to respond to NPPA. Since CAMTA1 expression is particularly 
low in the CD133+ fraction of many of our analyzed glioblastoma cell lines (suppl. Figure 3), 
it is tempting to speculate that the expression and also the sensitivity to the anti-proliferative 
peptide NPPA is repressed by miR-9/9* and miR-17 regulation of CAMTA1. 
Further analysis of the cellular functions of the tumor suppressor CAMTA1 as well as its 
regulators miR-9/9* may finally lead to a better understanding of glioblastoma pathogenesis 
and ultimately to more efficient therapies that might be based on miR-9 and miR-9* 
inhibitors. 
 
Materials and Methods 
Isolation of Ago2-associated RNAs  
R11 cells were reverse transfected in four 10 cm plates per sample with miR-122 (control) or 
miR-9* 2’-O-methylated antisense oligonucleotide inhibitors for 2d. Cells were lysed in 500 
l lysis buffer (150 mM KCl/25 mM Tris-HCl pH 7.5/2 mM EDTA/1mM NaF/0.5% NP-
40/0.5 mM DTT/0.5 mM AEBSF) per plate. Ribolock (Fermentas, 1l per ml of lysis buffer) 
was added before lysis. Lysates were cleared by centrifugation at 16000 g for 10 min. For 
immunoprecipitation (IP) of endogenous Ago2, 3 ml of monoclonal anti-Ago2 11A9 
hybridoma supernatant was coupled to 100 l protein G-Sepharose (GE Healthcare) for 10 h 
at 4°C. Coupled beads were washed twice with PBS and subsequently incubated with cell 
lysate for 4 h at 4°C. All IP samples were washed three times with IP wash buffer (300 mM 
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NaCl/50 mM Tris pH 7.5/1mM NaF, 0.01% NP-40/5 mM MgCl2) and once with PBS. IP 
samples and corresponding samples containing 10% of input lysate were proteinase K-
digested, followed by phenol/chloroform/isopropyl alcohol extraction and precipitation of 
RNA in 80% ethanol at -20°C. RNA was pelleted, dried and treated with DNaseI (Fermentas) 
for 45 min at 37°C, followed by thermal inactivation of DNaseI. RNA integrity was assessed 
via Agilent 2100 Bioanalyzer (Agilent Technologies) prior to microarray hybridization. 
 
Microarray experiments and data analysis 
RNA from anti-Ago2 IP and input samples was processed using the SuperAmp RNA 
amplification protocol (Miltenyi Biotec). cDNA integrity was checked via Bioanalyzer 
platform. 250 ng of each cDNA was labeled with Cy3 dye (Miltenyi Biotec) according to the 
manufacturer’s protocol. Samples were hybridized to Agilent Whole Human Genome 4x44 K 
Oligo Microarrays. Fluorescence signals of the hybridized Agilent Microarrays were detected 
using Microarray Scanner System (Agilent Technologies). 
Microarray data were analyzed using Agilent Genespring software. Expression values below 
0.01 were set to 0.01. Each measurement was divided by the 50th percentile of all 
measurements in that sample. All IP samples were normalized to the corresponding input 
RNA samples: The IP sample from control antagomir-transfected cells was normalized 
against the median of the corresponding input RNA sample and the IP sample from miR-9* 
antagomir-transfected cells was normalized against the median of the corresponding input 
RNA sample. For normalization, each measurement for each gene in the IP samples was 
divided by the median of that gene's measurements in the corresponding input RNA samples. 
IP to input ratios from miR-9* transfected samples were then devided by the IP to input ratios 
from control transfected sample. 
Using this normalization procedure, the normalized expression value of each transcript in IP 
samples directly reflects its fold enrichment in the immunoprecipitated transcript pool relative 
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to the input RNA pool. To filter for potential miRNA target mRNAs bound by Ago2, all 
transcripts that were >5-fold enriched in IPs from control antagomir-transfected cells were 
identified. Transcripts where the enrichment in miR-9* antagomir-transfected cells was >10-
fold lower than in control-transfected cells were considered to be potential targets of miR-9*. 
 
Cell culture and transfection 
R11, R20, R28, R40, R44, and R52 cells were cultured at 37°C in DMEM-F12 medium 
supplemented with 20 ng/mL of each human recombinant epidermal growth factor, human 
recombinant basic fibroblast growth factor (both from R&D Systems), and human leukemia 
inhibitory factor (Millipore), 2% B27 supplement (Invitrogen), 1% penicillin/streptomycin 
solution (PAA), and 1% MEM vitamins solution (Invitrogen). Cells were passaged every 7-10 
days by trypsinization or by detaching with a pipette. 50% of the medium was substituted 
twice weekly. HEK 293T, T98G and LNT-229 cells were cultured in DMEM supplemented 
with 10% fetal bovine serum and 1% penicillin/streptomycin solution. Typically, cells were 
passaged every 3 days by trypsinization in a 1:10 ratio.  
R11 cells (1x105 cells per well) were reverse transfected with 100 nM 2’-O-methyl 
oligonucleotides or 40 nM siRNAs in 6 well plates with 5 L/well Lipofectamine 2000 
(Invitrogen). For cotransfection of two 2’-O-methyl antisense oligonucleotides, each oligo 
was added to 50 nM final concentration, to give an overall concentration of 100 nM. The 
transfection mix was removed 24 h post transfection, and fresh medium was added. T98G 
cells were transfected with Lipofectamine 2000 12 h after seeding according to the 
manufacturer’s instructions, using 40 nM siRNAs or 80 nM 2’-O-methyl oligonucleotides. 
For plasmid transfections, R11, R28 and R28-luc cells were electroporated using the 
Nucleofector Kit for mouse neural stem cells (Lonza), according to the manufacturer’s 
instructions and the Nucleofector Device II (Lonza). In short, cells were detached by 
pipetting, washed once with DMEM/F12 and 3x106 cells were transfected with 5 ug of 
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plasmid DNA using Program A-033. Directly after electroporation, cells were transferred into 
one well of a 6-well plate. Medium was replaced 24 h post transfection. For electroporation of 
LNT-229 , the cell line nucleofector Kit R (Lonza) was used as described above. 
 
Western Blotting and Northern Blotting 
To analyze levels of proteins other than CAMTA1, cells were lysed as previously described 
(Weinmann et al, 2009). For the analysis of CAMTA1 protein levels or corresponding loading 
controls, cells were lysed in nuclear lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris pH 8, 
0.1 % sodium deoxycholate, 2 mM 4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride, 
5 units/ml DNAaseI (Fermentas)) for 20 min and sonicated for 10s on a Bandelin Sonopuls 
HD2070 sonifier. Lysates were cleared by centrifugation. Western Blotting was performed as 
previously described (Hock et al, 2007). The following antibodies (dilutions) were used: Anti-
mouse-HRP (1:5000), anti-rabbit-HRP (1:5000), mouse-anti--Actin AC15 (1:10000), 
mouse-anti-Tuj1 (1:1000), rabbit-anti-GFAP (1:2000), rabbit-anti-CAMTA1 (1:200). 
Northern blotting was performed as previously described (Lagos-Quintana et al, 2001) using 
either 2’-O-methyl oligonucleotide or DNA probes antisense to the miRNA of interest. The 
sequence of Ile tRNA probe was 5’-TGCTCCAGGTGAGGATCGAAC. 
 
Clonogenicity assays 
1x105 R11 cells were transfected in 6-well plates as indicated. 2’-O-methylated antisense 
oligonucleotides and synthetic miRNAs were transfected twice with an interval of 7d. 7d after 
second transfection, cells were counted and approximately 1000 cells were transferred into 
each well of a 48-well plate. Neurosphere-like clones were counted 4 weeks after plating. The 
number of clones per well were summed up for each sample and normalized to the number of 
clones obtained for control-transfected samples. Results of the described clonogenicity assays 
were reproduced by limited dilution assays with 1 cell per well. Herefore, 1x105 cells were 
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transfected as indicated above. 7d after second transfection, 1 cell was seeded into each well 
of a 96-well plate and neurosphere-like clones were counted 4 weeks after plating. Data for 
limited dilution assays are not shown. 
 
In vivo tumor model and bioluminescence imaging 
Intracranial glioblastoma xenografts were established in 10 week old male NMRI:nu/nu mice 
(Charles River) as described previously (Beier et al, 2007). In brief, tumor cells were treated 
as indicated. 3 h after transfection, 1.4 x 105 viable cells (as determined by trypan blue 
exclusion) were injected 2mm lateral to the midline and 4mm anterior to bregma to a depth of 
3mm using a Hamilton syringe. The bioluminescence of implanted tumor cells was 
determined 15 d after implantation. 1 min after injection of 150 mg/kg D-luciferin (Biosynth) 
mice were anesthetized and emitted photons were registered for 5 min using Xenogen IVIS 
Lumina Imaging System (Caliper Life Sciences). The signal was normalized to background 
signal. Mice without detectable tumors were excluded from the analysis. 
 
Lentiviral transduction of R28 cells 
Glioblastoma stem cells were stably transduced using a lentiviral vector expressing firefly 
luciferase under control of the constitutive spleen focus forming virus LTR promoter. 
Third generation packaging, VSV-pseudotyped, self-inactivating lentiviral vectors were 
produced by transient transfection of HEK 293T cells using standard protocols (Wubbenhorst 
et al, 2010). Medium was changed to stem cell medium after 24 h. Supernatants were filtered 
through 0.45 µm filter and used for spin infection (Leisegang et al, 2008). Individual wells of 
a 24-well plate were coated with 400 µl RetroNectin (Takara Bio Europe SAS; final 
concentration 12.5 µg/ml) for two hours at room temperature, subsequently incubated for 30 
min. at 37°C with bovine serum albumine (2 % in PBS) and washed with PBS prior to 
addition of cells. 1  105 cells/ml suspension cells were added onto RetroNectin coated wells. 
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One ml virus containing supernatant supplemented with protamine sulfate (final concentration 
4 µg/ml) was added to each well and infection was enhanced by 90 min centrifugation at 
32°C and 800  g. Cells were incubated at 37°C. The next day, cells were washed off the 
wells, spun, resuspended in 5 ml fresh complete medium and further cultivated. 
 
Cell lines 
The generation of R11, R20, R28, R40, R44, and R52 cell lines from glioblastoma samples 
was previously described (Beier et al, 2007). 
 
Antibodies 
The following antibodies were used: Rat-anti-hsAgo2 (11A9, (Rudel et al, 2008)), mouse-
anti-Tuj1 MMS-435p (Covance), mouse-anti--Actin AC15 (Abcam), rabbit-anti-GFAP 
(DAKO), anti-CD133-2 293C3-PE (Miltenyi), anti-rabbit-HRP, anti-mouse-HRP (both from 
Sigma). The polyclonal antibody to CAMTA1 was generated as follows: A GST-tagged 
fragment containing aa 294-864 of CAMTA1 was expressed in E. coli and used for the 
immunization of rabbits. Polyclonal antiserum was purified and used for western blotting. 
 
Oligonucleotides 
2’-O-methyl antisense oligonucleotides and siRNAs/miRNAs were chemically synthesized 
using RNA phosphoramidites (Pierce) on an Äkta Oligopilot 10 DNA/RNA synthesizer (GE 
Healthcare), according to the manufacturer’s protocol. The sequences of 2’-O-methyl 
oligonucleotides were miR-9* antisense, 5’-ACUUUCGGUUAUCUAGCUUUAT; miR-17-
5p antisense, 5’- ACUACCUGCACUGUAAGCACUUUGT; miR-106b antisense, 5’- 
AUCUGCACUGUCAGCACUUUAT; miR-9 antisense, 5’-
UCAUACAGCUAGAUAACCAAAGAT; miR-122 antisense, 5’-
ACAAACACCAUUGUCACACUCCAT; miR-301 antisense, 5’-
 19
GCUUUGACAAUACUAUUGCACUGT; miR-330 antisense, 5’-
GCCUAAGACACAGGCCCAGAGAT. The siRNA sequences (sense, antisense) were 
CAMTA1 siRNA 1, 5’-CTACCGAAGTTATAAGAAAUT, 
5’-TTTCTTATAACTTCGGTAGUT; CAMTA1 siRNA 2, 
5’-GAAUCAAGCAGGAGAAUUUUT, 5’-AAAUUCUCCUGCUUGAUUCGT; control 
siRNA 1, 5’-UUGUCUUGCAUUCGACUAAUT, 5’-UUAGUCGAAUGCAAGACAAUT; 
control siRNA 2, 5’-UCGAAGUAUUCCGCGUACGUT, 5’-
CGUACGCGGAAUACUUCGAUT. The sequences of synthetic miRNAs were miR-9, 5’-
UCUUUGGUUAUCUAGCUGUAUGAT; miR-9*, 5’-
AUAAAGCUAGAUAACCGAAAGUT; miR-122, 5’-
UGGAGUGUGACAAUGGUGUUUGT, miR-122*, 
AACGCCAUUAUCACACUAAAUAT. 
 
Flow cytometry 
Cells were trypsinized and washed with DMEM-F12 and FACS buffer (PBS containing 1% 
BSA). 107 cells were resuspended in 80 L FACS buffer containing 10% FcR blocking 
reagent (Miltenyi) and incubated for 5 min on ice. 10 L Anti-CD133-PE was added, and 
cells were incubated for 10 min on ice in the dark. Cells were pelleted and washed once with 
FACS buffer. Stained cells were sorted on a FACS Aria system (Becton Dickinson). Cell 
debris were gated out using a forward scatter/sideward scatter dot plot. CD133-negative and -
positive cell populations were identified using unstained cells as control.  
 
RNA isolation 
Total RNA for mRNA analyses was isolated using the Prep Ease kit (USB), according to the 
manufacturer’s instructions. For small RNA detection, RNA was isolated using Trifast 
(Peqlab).  
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 cDNA synthesis 
cDNA for mRNA analysis was synthesized with random hexamer primers from 2 g of total 
RNA using the First Strand cDNA synthesis kit (Fermentas), according to the manufacturer’s 
protocol. To quantify miRNAs, RNA samples were treated with DNaseI (Fermentas), 
poly(A)-tailed using the poly(A)-tailing kit (Ambion) and reverse transcribed using the First 
Strand cDNA synthesis kit and the URT primer 
AACGAGACGACGACAGACTTTTTTTTTTTTTTTV (Hurteau et al, 2006). 
 
qPCR 
qPCR was performed on a MyiQ cycler (BioRad) using the Mesa Green qPCR mastermix 
(Eurogentec). The primers were: GAPDH, 5’-TGGTATCGTGGAAGGACTCATGAC, 5’-
ATGCCAGTGAGCTTCCCGTTCAGC; -Actin, 5’-CTGGAGAAGAGCTACGAGCTG, 
5’-TTGAAGGTAGTTTCGTGGATG; CAMTA1, 5’-ATCCTTATCCAGAGCAAATTCC, 
5’-AGTTTCTGTTGTACAATCACAG; NPPA, 5’-CAGGATGGACAGGATTGGA, 5’-
TCTTCAGTACCGGAAGCTGTT; NPR-A 5’-TCGAAACCACCAAACTCCTC, 5’-
AGTGGTGGGACTGAAGATGC; hsa-miR-9, 5’-TCTTTGGTTATCTAGCTGTATG; hsa-
miR-9*, 5’-ATAAAGCTAGATAACCGAAAG; hsa-miR-34a; 5’-
TGGCAGTGTCTTAGCTGGTTG; U6 snRNA, 5’-GATGACACGCAAATTCGTGAAG; 
Universal RT primer for miRNA and U6 snRNA detection, 5’-
AACGAGACGACGACAGACTTT. Data were evaluated using the ddCt method with 
GAPDH or -Actin as reference mRNAs. Error bars were obtained from triplicate PCR 
samples by propagating the ddCt standard error of the mean through the exponential term as 
previously described (Livak & Schmittgen, 2001). 
 
Generation and sequencing of small RNA libraries 
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Small RNA libraries were generated by Vertis Biotechnology AG and sequenced by 454 
pyrosequencing as previously described (Tarasov et al, 2007). 
 
Analysis of the sequencing results 
Known miRNAs were identified by comparing the sequencing results with annotated 
miRNAs from the H. sapiens miRNA database (miRBase) using the Microsoft Excel 
software. Several miRNA reads were found to contain sequencing errors, typically starting 
from nucleotide 18-25 that were possibly due to the procedure of library preparation and/or 
pyrosequencing. Most errors were poly(A) insertions at the 3’-end of the reads. Therefore, 
those reads that were fully complementary to a known miRNA from nucleotide 1-18 but had 
additional A insertions at the 3’-end were re-annotated as miRNAs. 
Read numbers for each miRNA were normalized to the total number of reads of the 
corresponding library. For calculation of miRNA expression, the normalized reads numbers 
from the CD133-negative cell library were divided by the normalized read numbers from the 
CD133-negative library. 
 
Luciferase assays 
To investigate miRNA effects on reporter constructs, T98G were used for high transfection 
efficiency and high firefly and renilla expression levels.  T98G cells were co-transfected with 
2’-O-methylated antisense oligonucleotides (80 nM final concentration) and pMIR-RL 
constructs (100 ng per well) in 48-well plates, using Lipofectamine 2000. 24 h after 
transfection, cells were lysed in passive lysis buffer (Promega). Luciferase activities were 
measured on a Mithras LB 940 luminometer (Berthold technologies). Luciferase substrate 
reagents were purchased from PJK cryosystems. All samples were assayed in 4 to 6 
replicates. Firefly/renilla luminescence ratios for individual samples were normalized to 
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corresponding ratios of the empty pMIR-RL plasmid and control inhibitor transfected 
samples. 
 
Plasmids 
The pMIR-RL dual luciferase vector was previously described (Beitzinger et al, 2007). The 
3’-UTR of CAMTA1 mRNA was PCR-amplified from R28 genomic DNA using the primers 
5’-ATACGAGCTCAGACATACAGCAGCATCCCTTAGCAATGTG (forward), 5’- 
ATACGCCGGCGGAAATTTTCTTCATTTTTAATTTACAGCAG (reverse), digested with 
SacI and NaeI and ligated into pMIR-RL. For the analysis of miR-9 and miR-9* binding sites, 
all sites predicted by TargetScan 5.0 and all seed matches that are conserved in mammals and 
indicated in Fig. 3A were mutated by PCR-based mutagenesis as follows: The nucleotides 
CAAA in miR-9* seed matches were replaced by GTTT, and the nucleotides CTTT in miR-
9* seed matches were replaced by GAAA. A cDNA fragment encoding CAMTA1 was PCR-
amplified from Marathon whole human brain cDNA library (BD Bioscience). CAMTA1 orf 
was re-amplified by using the primers 5’- 
ATACGATATCATGTGGCGCGCGGAGGGGAAATG (forward) and 5’- 
ATATGCGGCCGCTCAAGTTCCTTGGCCTTTTTCAATTCTTTCACTC (reverse) bearing 
EcoRV and NotI restriction sites, respectively, followed by restriction digestion and ligation 
into pIRESneo. Note that all CAMTA1 clones that were obtained contained an additional 
exon of 21 nt in size (AGCTGACATGGATAGCCTTGA, data not shown) compared to the 
Refseq sequence (NM_015215.1). The additional nucleotides are inserted after nt 4687 of 
NM_015215.1 and encode for 7 additional amino acids which localize to the predicted 
Calmodulin binding domain. An N-terminal CAMTA1 deletion mutant lacking the amino 
acids 1-188 (nt 1-564) was cloned into pIRESneo and used as a control. All constructs were 
verified by sequencing. 
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Analysis of gene expression in glioma patients and correlation with survival  
The results published here are in part based upon data generated by the Repository of 
Molecular Brain Neoplasia Data (Rembrandt), a project led by the National Cancer Institute 
(NCI) (The Cancer Genome Atlas, 2008; Madhavan et al, 2009). Information about the 
Rembrandt Database can be found at https://caintegrator.nci.nih.gov/rembrandt/. TCGA 
project is a joined effort of the NCI and the National Human Genome Research Institute 
(NHGRI) (The Cancer Genome Atlas, 2008). Information about TCGA can be found at 
http://cancergenome.nih.gov.  
 
Statistical analysis 
Experiments were performed in three biological replicates, unless stated otherwise. Mean 
values and standard error of the mean (SEM) were calculated from all biological replicates. 
Error bars display +/- SEM. Significance was assessed from biological replicates using two-
sided Student’s t-tests for unequal sample variance. P-values <0.05 were considered as 
significant. 
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Figure legends 
Figure 1: miRNA expression profile of CD133+ vs. CD133- glioblastoma cells. (A)/(B) 
Glioblastoma stem cells were sorted from primary glioblastoma cells (R11) and miRNA 
expression was analyzed by cloning and deep sequencing. (C) RNA composition of the 
libraries. (D) Comparison of the CD133+ (positive value) and CD133- (negative value) 
miRNA expression profiles. The circle sizes indicate the abundance of the miRNA. (E) 
Validation of miR-17-5p, miR-9*, miR-106b and miR-9 in CD133+ glioblastoma cells (R11) 
by Northern blotting. Ile tRNA served as loading control. (F) Validation of the differential 
expression of miR-9 (upper panel), miR-9* (middle panel) and miR-34a (control, lower 
panel) in different glioblastoma cell lines. 
 
Figure 2: miR-9/9* affect neurosphere formation and neuronal differentiation of glioblastoma 
stem cells. (A) miR-9*, miR-9, miR-17-5p and miR-106b were inhibited using 2’-O-
methylated antisense oligonucleotides and neurosphere formation was analyzed in R11 cells. 
(B) A miR-9/9* mimic was transfected into primary glioblastoma cells (R11) and colony 
formation was analyzed. (C) Lower concentrations of inhibitors against miR-9/9* and miR-17 
were co-transfected into R11 cells together with a control inhibitor or a miR-17 inhibitor and 
neurosphere formation was analyzed. (D) miR-9/9* were inhibited by antisense inhibitors in 
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primary glioblastoma cells (R11) and CD133+ cells were analyzed by FACS. (E) miR-9/9* 
was inhibited as described above and the neuronal differentiation marker Tuj1 (upper panels), 
the glial differentiation marker GFAP (middle panels) were analyzed by Western blotting. -
actin (lower panels) was analyzed as loading control. In Figure 2A-E, significance was 
assessed by two-sided Student's t-test (* p<0.05, ** p<0.01, *** p<0.001, n.s. = not 
significant). 
 
Figure 3: Identification of mir-9* target mRNAs. (A) Strategy to identify miR-9* target 
mRNAs. (B) List of most strongly Ago2-associated transcripts in primary glioblastoma cell 
line R11 in the presence of a miR-9* or miR-122 control inhibitor. miR-9* target mRNA 
candidates that were >10-fold depleted in the miR-9* inhibitor sample compared to the 
control are displayed in bold letters. 
 
Figure 4: miR-9/9* regulate CAMTA1 expression. (A) Location of miR-9 (blue), miR-9* 
(red), miR-17-5p (yellow) and miR-106b (brown) on the 3’ UTR of CAMTA1. (B) The 
CAMTA1 3’ UTR or variants with mutated miR-9 (1) or miR-9* (2) binding sites were fused 
to luciferase and luciferase expression was investigated in the presence or absence of miR-9 
(1) or miR-9* (2) inhibitors in T98G cells. Panel (3) shows inhibitory effects of miR-106b 
and miR-17-5p on the wild type CAMTA1 3’ UTR. (C) mRNA levels of CAMTA1 were 
analyzed by qPCR upon miR-9 or miR-9* inhibition by antisense oligonucleotides in R11 
cells. (D) CAMTA1 protein levels were analyzed upon miR-9 or miR-9* inhibition in R11 
cells. Western blotting with a anti--actin antibody was used as loading control. (E) Primary 
glioblastoma cells (R11) were pre-treated with two different siRNAs against CAMTA1 for 
CAMTA1 depletion. Subsequently, neurosphere formation assays were performed as 
described in Figure 2A using miR-9 or miR-9* inhibitors. 
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Figure 5: CAMTA1 has tumor suppressor activity in vitro. (A) Domain organization of 
CAMTA1 and the CAMTA1N, where the DNA-binding domain has been deleted. (B) 
Flag/HA-tagged CAMTA1 (FH-CAMTA1) as well as FH-CAMTA1N was expressed in 
HEK 293T cells and protein expression was analyzed by Western blotting using an anti-
CAMTA1 antibody. (C) FH-CAMTA1 was expressed in two different primary glioblastoma 
cells (R11, left panel and R28, right panel) and neurosphere formation was analyzed. (D) 
CAMTA1 and CAMTA1N were expressed in R11 cells and neurosphere formation was 
analyzed. (E) CAMTA1 was expressed in primary glioblastoma cells (R11) and the CD133+ 
cell population was analyzed by flow cytometry. 
 
Figure 6: CAMTA1 regulates tumor growth in an in vivo xenograft model. R28 cells, stably 
transfected with luciferase, were transfected with pIRES or pIRES-CAMTA1. Cells were then 
intracranially injected into mice brains. Tumor growth was quantified by measurement of 
luciferase activity 15 days after implantation. (A) Dorsal views of two representative mice are 
depicted from pIRES and pIRES-CAMTA1 group. The color scales indicate the signal 
intensity at the surface of the animals recorded as total photons per second, square centimeter 
and steradian (p/s/cm2/sr). (B) Box-Plots of the quantified dorsal signals from both groups. 
Statistical significance was calculated with two-sided Student‘s ttest (* p<0,05). 
 
Figure 7: CAMTA1 expression correlates with patient survival (A, B) CAMTA1 mRNA 
expression was analyzed in non-tumor brain tissue, WHO grade I-III astrocytoma and 
glioblastoma using the indicated affymetrix probes on a U-133A microarray. (C) Kaplan-
Meier survival plot for glioblastoma patients with high, low and intermediate CAMTA1 
mRNA expression, as determined by affymetrix probe 213268 on a U-133A microarray. Data 
were obtained from the Rembrandt and the TCGA databases (see Materials and Methods). 
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Figure 8. CAMTA1 regulates the peptide hormone NPPA and its receptor NPR-A. (A)/(B) 
CAMTA1 overexpression increases NPPA (A) and NPR-A mRNA levels (B). LNT-229 cells 
were transfected with indicated plasmids and NPPA or NPR-A mRNA levels were 
determined by qRT-PCR. Data were normalized to GAPDH mRNA levels as well as to the 
empty pIRES plasmid. (C) Inhibition of miR-9 and miR-9* increases NPPA and NPR-A 
mRNA levels. LNT-229 cells were transfected with indicated 2‘-O-methyl antisense 
oligonucleotides and NPPA or NPR-A mRNA levels were determined by qRT-PCR. Data 
were normalized to GAPDH mRNA levels and control inhibitor transfected samples. (D) 
NPPA expression correlates with glioma outcome. Kaplan-Meier survival plot for glioma 
patients (glioblastoma multiforme, oligodendroglioma, astrocytoma) with high, low and 
intermediate NPPA mRNA expression. Data were generated to Affymetrix probe 209957 on a 
U-133A microarray. 
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Supplementary material 
 
Supplementary Figure legends 
Supplemental Figure 1: miR-9 and miR-9* can be independently depleted by using 2’-O-
methyl antisense oligonucleotides. A) R11 cells were transfected twice with antagomirs. RNA 
was isolated and miRNA levels were analyzed by qPCR relative to U6 snRNA expression and 
to control inhibitor-transfected samples. B) R11 cells were treated as in A. RNA was isolated 
and analyzed for hsa-miR-9 and hsa-miR-9* levels by Northern Blotting, using Ile tRNA as 
loading control. 
 
Supplemental Figure 2: CAMTA1 knockdown in R11 cells. R11 cells were transfected with 
two different CAMTA1 siRNAs. A) CAMTA1 mRNA levels were quantified by qRT-PCR 
and normalized to GAPDH. B) Levels of endogenous CAMTA1 protein and -Actin were 
analyzed by Western Blotting. C) The CAMTA1 signals obtained by Western Blotting were 
quantified relative to -Actin signals. 
 
Supplemental Figure 3: CAMTA1 mRNA expression in CD133+ and CD133- cells. (A) 
CD133+ and CD133- cells of the indicated cell lines (R11, R28, R40, R44, R54) were 
separated by FACS sorting, mRNA was extracted and CAMTA1 mRNA levels were 
determined by qPCR. (B) CD133+ and CD133- cells derived from the R28 cell line were 
analyzed by western blotting with antibodies against CAMTA1 (upper panel) or ß-actin 
(lower panel).  
 Supplemental table 1: Composition of the individual deep sequencing libraries 
 reads reads 
RNA class CD133-negative cells CD133-positive cells 
total reads 76339 65536 
miRNA 48834 30452 
rRNA 5253 4060 
tRNA 5144 4924 
other noncoding RNAs 1699 3303 
other sequences 15409 22797 
 
 Supplemental table 2: miRNA composition of the individual deep sequencing libraries 
miRNA reads (CD133-) reads (CD133+) reads (both libraries) 
hsa-miR-16  4829 2954 7783 
hsa-miR-15b  2443 3774 6217 
hsa-miR-21  4129 704 4833 
hsa-miR-221  3973 208 4181 
hsa-miR-23a  2763 1299 4062 
hsa-miR-9*  653 2250 2903 
hsa-miR-25  1402 1294 2696 
hsa-miR-106b  704 1688 2392 
hsa-miR-320  1035 1191 2226 
hsa-miR-17 441 1691 2132 
hsa-miR-23b  1005 1084 2089 
hsa-miR-27a  1853 210 2063 
hsa-miR-151-5p  688 948 1636 
hsa-miR-27b  1099 530 1629 
hsa-miR-103  1041 728 1769 
hsa-miR-9  841 719 1560 
hsa-miR-15a  871 673 1544 
hsa-miR-191  750 641 1391 
hsa-miR-26a  963 327 1290 
hsa-miR-222  1166 64 1230 
hsa-miR-92a  479 519 998 
hsa-let-7a  550 428 978 
hsa-miR-93  550 402 952 
hsa-miR-424  528 392 920 
hsa-miR-26b  478 383 861 
hsa-miR-20a  422 392 814 
hsa-miR-31  733 13 746 
hsa-miR-24  639 65 704 
hsa-miR-374b  277 351 628 
hsa-miR-30b  475 82 557 
hsa-miR-125b  370 149 519 
hsa-miR-195  353 154 507 
hsa-miR-29a  415 79 494 
hsa-let-7b  387 93 480 
hsa-miR-30c  408 61 469 
hsa-miR-128a  120 342 462 
hsa-miR-204  422 11 433 
hsa-miR-34a  427 5 432 
hsa-miR-151-3p  287 139 426 
hsa-miR-31*  398 4 402 
hsa-miR-361-5p  183 191 374 
hsa-miR-92b  201 130 331 
hsa-let-7g  206 79 285 
hsa-miR-497  244 41 285 
hsa-let-7f  223 44 267 
hsa-miR-140-3p  146 96 242 
hsa-miR-199a-3p  127 102 229 
hsa-miR-423-3p  178 49 227 
hsa-miR-125a-5p  177 49 226 
hsa-miR-152  185 41 226 
hsa-miR-22  199 22 221 
hsa-miR-196a  42 122 164 
hsa-miR-30d  153 10 163 
hsa-let-7c  127 33 160 
hsa-let-7d*  51 103 154 
hsa-miR-378  129 22 151 
hsa-miR-345  100 50 150 
hsa-miR-28-5p  116 30 146 
hsa-miR-153  126 18 144 
hsa-miR-21*  119 22 141 
hsa-miR-30a  133 8 141 
hsa-miR-28-3p  90 47 137 
hsa-miR-20b  54 79 133 
hsa-miR-130b  82 48 130 
hsa-miR-99b  79 49 128 
hsa-miR-484  111 16 127 
hsa-miR-99a  90 27 117 
hsa-miR-149  113 2 115 
hsa-miR-185  71 44 115 
hsa-miR-374a  102 13 115 
hsa-miR-425  63 52 115 
hsa-miR-148a  108 4 112 
hsa-miR-22*  76 35 111 
hsa-miR-29c  86 23 109 
hsa-miR-130a  66 38 104 
hsa-miR-17*  46 58 104 
hsa-miR-652  55 49 104 
hsa-miR-181b  83 20 103 
hsa-miR-30a*  66 35 101 
hsa-miR-30e  79 19 98 
hsa-miR-106a  31 61 92 
hsa-miR-190  58 34 92 
hsa-miR-210  16 76 92 
hsa-miR-218  81 11 92 
hsa-miR-455-3p  72 20 92 
hsa-miR-16-2*  78 13 91 
hsa-miR-182  44 46 90 
hsa-miR-450a  81 9 90 
hsa-miR-106b*  37 43 80 
hsa-miR-100  63 13 76 
hsa-miR-30e*  29 42 71 
hsa-let-7b*  60 8 68 
hsa-miR-181a  50 17 67 
hsa-miR-532-3p  27 36 63 
hsa-miR-101  37 25 62 
hsa-let-7e  34 26 60 
hsa-miR-187  56 4 60 
hsa-miR-590-3p  44 16 60 
hsa-miR-532-5p  21 38 59 
hsa-miR-107  135 90 225 
hsa-miR-671-5p  55 3 58 
hsa-miR-744  35 23 58 
hsa-miR-324-3p  34 22 56 
hsa-miR-183  19 35 54 
hsa-miR-221*  45 8 53 
hsa-miR-155  48 4 52 
hsa-miR-454  39 11 50 
hsa-let-7a*  45 4 49 
hsa-let-7d  20 29 49 
hsa-miR-199a-5p  48 0 48 
hsa-miR-103-2* 21 26 47 
hsa-miR-138  22 25 47 
hsa-miR-424*  25 21 46 
hsa-miR-582-5p  44 2 46 
hsa-let-7i  40 5 45 
hsa-miR-193b  39 6 45 
hsa-mir-1271 20 23 43 
hsa-miR-488  8 34 42 
hsa-miR-301a  30 10 40 
hsa-miR-615-3p  9 29 38 
hsa-miR-887  28 10 38 
hsa-miR-19b  33 3 36 
hsa-miR-503  19 17 36 
hsa-miR-378*  24 11 35 
hsa-miR-423-5p  24 9 33 
hsa-miR-138-1*  6 26 32 
hsa-miR-1307 21 11 32 
hsa-miR-140-5p  23 9 32 
hsa-miR-574-3p  26 4 30 
hsa-let-7f-1*  22 7 29 
hsa-miR-365  27 1 28 
hsa-miR-340*  5 21 26 
hsa-let-7f-2*  12 13 25 
hsa-miR-10b  14 11 25 
hsa-miR-132  12 13 25 
hsa-miR-148b  22 2 24 
hsa-miR-186  22 2 24 
hsa-miR-342-3p  23 1 24 
hsa-miR-145  22 0 22 
hsa-miR-421  16 6 22 
hsa-miR-598  8 14 22 
hsa-miR-7-1*  5 17 22 
hsa-miR-505  20 1 21 
hsa-miR-197  15 4 19 
hsa-miR-200c  13 6 19 
hsa-miR-339-3p  19 0 19 
hsa-miR-34b*  17 1 18 
hsa-miR-224  12 5 17 
hsa-miR-29b  13 4 17 
hsa-miR-483-5p  0 17 17 
hsa-miR-500*  9 8 17 
hsa-miR-590-5p  16 1 17 
hsa-miR-339-5p  16 0 16 
hsa-miR-340  3 12 15 
hsa-miR-361-3p  12 3 15 
hsa-miR-574-5p  8 7 15 
hsa-miR-886-5p  10 5 15 
hsa-miR-98  9 6 15 
hsa-miR-766  9 5 14 
hsa-miR-99a*  12 2 14 
hsa-miR-328  13 0 13 
hsa-miR-33a*  11 2 13 
hsa-miR-362-3p  13 0 13 
hsa-miR-500  3 10 13 
hsa-miR-584  8 5 13 
hsa-miR-769-5p  10 3 13 
hsa-miR-93*  12 1 13 
hsa-let-7e*  4 8 12 
hsa-miR-125b-2*  10 2 12 
hsa-miR-181a-2*  3 9 12 
hsa-miR-96  10 2 12 
hsa-miR-146b-5p  9 2 11 
hsa-miR-324-5p  7 4 11 
hsa-miR-363  7 4 11 
hsa-miR-95  0 11 11 
hsa-let-7i*  10 0 10 
hsa-miR-10a  10 0 10 
hsa-miR-124  1 9 10 
hsa-miR-181d  5 5 10 
hsa-miR-34c-3p  9 1 10 
hsa-miR-34c-5p  10 0 10 
hsa-miR-551b  2 8 10 
hsa-miR-190b  0 9 9 
hsa-miR-205  9 0 9 
hsa-miR-335  6 3 9 
hsa-miR-501-3p  6 3 9 
hsa-miR-768-3p  8 1 9 
hsa-miR-15b*  8 0 8 
hsa-miR-301b  8 0 8 
hsa-miR-362-5p  8 0 8 
hsa-miR-550  6 2 8 
hsa-miR-671-3p  7 1 8 
hsa-miR-675  0 8 8 
hsa-miR-125a-3p  6 1 7 
hsa-miR-130b*  3 4 7 
hsa-miR-194  6 1 7 
hsa-miR-214  7 0 7 
hsa-miR-296-3p  3 4 7 
hsa-miR-32  7 0 7 
hsa-miR-199b-5p  2 4 6 
hsa-miR-483-3p  0 6 6 
hsa-miR-486-5p  4 2 6 
hsa-miR-550*  6 0 6 
hsa-miR-7  4 2 6 
hsa-miR-132*  4 1 5 
hsa-miR-181c*  0 5 5 
hsa-miR-18a  2 3 5 
hsa-miR-18b  2 3 5 
hsa-miR-193a-3p  5 0 5 
hsa-miR-200b  4 1 5 
hsa-miR-23b*  3 2 5 
hsa-miR-29b-1*  5 0 5 
hsa-miR-335*  5 0 5 
hsa-miR-33b*  2 3 5 
hsa-miR-374b*  3 2 5 
hsa-miR-455-5p  5 0 5 
hsa-miR-502-5p  0 5 5 
hsa-miR-624*  4 1 5 
hsa-miR-708  3 2 5 
hsa-miR-769-3p  3 2 5 
hsa-miR-886-3p  5 0 5 
hsa-miR-92b*  3 2 5 
hsa-miR-935  1 4 5 
hsa-let-7g*  3 1 4 
hsa-miR-126  2 2 4 
hsa-miR-135b  4 0 4 
hsa-miR-212  2 2 4 
hsa-miR-25*  3 1 4 
hsa-miR-27b*  2 2 4 
hsa-miR-29a*  4 0 4 
hsa-miR-331-3p  3 1 4 
hsa-miR-34b  3 1 4 
hsa-miR-501-5p  4 0 4 
hsa-miR-513-5p  4 0 4 
hsa-miR-628-3p  1 3 4 
hsa-miR-874  3 1 4 
hsa-miR-942  3 1 4 
hsa-miR-125b-1*  2 1 3 
hsa-miR-137  3 0 3 
hsa-miR-139-5p  0 3 3 
hsa-miR-146a  2 1 3 
hsa-miR-18a*  2 1 3 
hsa-miR-32*  1 2 3 
hsa-miR-330-3p  0 3 3 
hsa-miR-338-3p  0 3 3 
hsa-miR-34a*  2 1 3 
hsa-miR-425*  2 1 3 
hsa-miR-542-3p  3 0 3 
hsa-miR-628-5p  2 1 3 
hsa-miR-767-3p  0 3 3 
hsa-miR-877  1 2 3 
hsa-miR-885-5p  3 0 3 
hsa-miR-99b*  1 2 3 
hsa-mR-199a-3p  3 0 3 
hsa-miR-126*  0 2 2 
hsa-miR-135a  0 2 2 
hsa-miR-146b-3p  2 0 2 
hsa-miR-149*  1 1 2 
hsa-miR-15a*  1 1 2 
hsa-miR-181a*  1 1 2 
hsa-miR-193b*  2 0 2 
hsa-miR-20b*  1 1 2 
hsa-miR-219-5p  2 0 2 
hsa-miR-30d*  1 1 2 
hsa-miR-326  1 1 2 
hsa-miR-331-5p  1 1 2 
hsa-miR-488*  0 2 2 
hsa-miR-551b*  2 0 2 
hsa-miR-582-3p  1 1 2 
hsa-miR-643  0 2 2 
hsa-miR-660  2 0 2 
hsa-miR-760  2 0 2 
hsa-miR-885-3p  0 2 2 
hsa-miR-888  0 2 2 
hsa-miR-940  1 1 2 
hsa-miR-941  2 0 2 
hsa-miR-100*  1 0 1 
hsa-miR-105  0 1 1 
hsa-miR-10a*  1 0 1 
hsa-miR-129*  0 1 1 
hsa-miR-129-5p  1 0 1 
hsa-miR-135a*  0 1 1 
hsa-miR-135b*  1 0 1 
hsa-miR-138-2*  0 1 1 
hsa-miR-141  1 0 1 
hsa-miR-143  1 0 1 
hsa-miR-143*  1 0 1 
hsa-miR-181c  0 1 1 
hsa-miR-183*  0 1 1 
hsa-miR-184  0 1 1 
hsa-miR-192  0 1 1 
hsa-miR-193a-5p  1 0 1 
hsa-miR-195*  1 0 1 
hsa-miR-20a*  1 0 1 
hsa-miR-219-1-3p  0 1 1 
hsa-miR-24-1*  0 1 1 
hsa-miR-24-2*  1 0 1 
hsa-miR-26b*  1 0 1 
hsa-miR-296-5p  1 0 1 
hsa-miR-29b-2*  1 0 1 
hsa-miR-30c-1*  1 0 1 
hsa-miR-338-5p  0 1 1 
hsa-miR-33a  1 0 1 
hsa-miR-342-5p  0 1 1 
hsa-miR-451  1 0 1 
hsa-miR-499-5p  1 0 1 
hsa-miR-524-5p  1 0 1 
hsa-miR-545  1 0 1 
hsa-miR-556-3p  1 0 1 
hsa-miR-570  0 1 1 
hsa-miR-625  1 0 1 
hsa-miR-629*  1 0 1 
hsa-miR-641  0 1 1 
hsa-miR-7-2*  1 0 1 
hsa-miR-744*  0 1 1 
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